Steven Jon Russell Sells 1,026 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Steven Jon Russell sold 1,026 shares of Beta Bionics stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $12.36, for a total value of $12,681.36. Following the completion of the transaction, the insider directly owned 179,096 shares in the company, valued at $2,213,626.56. This represents a 0.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Beta Bionics Trading Down 1.6%

BBNX stock opened at $11.38 on Thursday. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $32.71. The firm has a market capitalization of $505.04 million, a PE ratio of -5.84 and a beta of 5.60. The firm has a 50-day moving average of $18.35 and a two-hundred day moving average of $22.35.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The business had revenue of $32.12 million for the quarter.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Recent operational/analyst context supports longer‑term upside — Beta Bionics beat EPS estimates in its Feb. 17 quarter and the consensus analyst view remains a “Moderate Buy” with a $23.20 average price target, providing a counterbalance to near‑term selling. MarketBeat coverage
• Neutral Sentiment: Short‑interest data published for early March shows implausible values (entries report “0 shares”/NaN and 0.0 days to cover), so there is no reliable signal from short sellers — treat reported short‑interest changes as inconclusive until corrected by exchanges or data providers.
• Negative Sentiment: A wave of small insider sell orders was disclosed in early March (including the CFO’s sale of 1,428 shares and several other executive sales at roughly $12.36 each). Multiple Form 4 filings and press coverage frame this as coordinated executive selling, which often pressures sentiment for small‑cap biotech/medical device stocks. TipRanks: Insiders Cash Out
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice seeking investors who experienced losses, increasing legal and reputational risk and likely weighing on near‑term sentiment until the matter is clarified. GlobeNewswire: Faruqi & Faruqi notice

Institutional Investors Weigh In On Beta Bionics

Several large investors have recently made changes to their positions in BBNX. Eventide Asset Management LLC raised its position in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after acquiring an additional 37,476 shares in the last quarter. Farallon Capital Management LLC grew its position in Beta Bionics by 2.6% in the third quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after acquiring an additional 110,000 shares in the last quarter. Soleus Capital Management L.P. grew its position in Beta Bionics by 12.5% in the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after acquiring an additional 424,817 shares in the last quarter. Sands Capital Alternatives LLC increased its stake in shares of Beta Bionics by 15.0% during the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after purchasing an additional 466,331 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after purchasing an additional 1,509,217 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BBNX shares. Robert W. Baird dropped their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. TD Cowen assumed coverage on Beta Bionics in a research report on Monday, January 26th. They set a “hold” rating and a $17.00 price objective for the company. Lake Street Capital set a $20.00 target price on Beta Bionics in a report on Wednesday, February 18th. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, Truist Financial lowered their price objective on shares of Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.